COLO B Coloplast A/S Class B

Coloplast US Named a 2020 Top Workplace

Coloplast US Named a 2020 Top Workplace

The company receives recognition for strong values and company culture. 

Coloplast US announced today that it is included among the Star Tribune’s Top 150 Workplaces in Minnesota. This is the first year the company has made the list, receiving recognition for its commitment to company culture, specifically around trust in leadership, well-informed employees, and strong company values. The company ranked #36 on the list.

The Star Tribune 150 recognizes the most progressive companies in Minnesota based on employee opinions measuring engagement, organizational health and satisfaction. The analysis included responses from more than 76,000 employees at nearly 3,000 Minnesota public, private and nonprofit organizations. Rankings were composite scores calculated purely on the basis of employee responses.

“Our employees are passionate about carrying out our mission of helping people with intimate healthcare needs, so they are able to live their lives with confidence. This recognition helps distinguish Coloplast as an employer of choice for people looking to advance their careers at a fast-growing, closely-knit company that prioritizes trust, collaboration, and open communication,” said Manu Varma, president and SVP of Chronic Care North America.

Star Tribune Publisher Michael J. Klingensmith said, “The companies in the Star Tribune Top 150 Workplaces deserve high praise for creating the very best work environments in the state of Minnesota. My congratulations to each of these exceptional companies.” 

is a medical device company that develops products and services designed to make life easier for people with intimate health conditions. Coloplast listens to its users to better understand their needs and responds by bringing the best ideas to market in the form of medical devices and service solutions.

Coloplast is growing and hiring for many positions. To see current job openings and learn how to join the Coloplast team, visit the company’s .

Contact

Lina Danstrup

Senior Media Relations Manager, Corporate Communications



Attachment

EN
25/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Coloplast AS: 1 director

A director at Coloplast AS bought 18,450 shares at 650.500DKK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående p...

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående personers handel med Coloplast-aktier Se venligst vedlagte pdf.   Vedhæftet fil

 PRESS RELEASE

Coloplast A/S - Trading in Coloplast shares by board members, executiv...

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Please see enclosed pdf.   Attachment

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
 PRESS RELEASE

Coloplast A/S - Selskabsmeddelelse nr. 04/2025 - Regnskabsmeddelelse, ...

Coloplast A/S - Selskabsmeddelelse nr. 04/2025 - Regnskabsmeddelelse, 1. halvår 2024/25 Delårsrapport, første halvår 2024/25  1. oktober 2024 – 31. marts 2025  Coloplast leverede 6% organisk vækst i 2. kvartal, påvirket af produkttilbagekaldelsen i Urologi og et svagt kvartal i Stomi. Overskudsgraden1 i 2. kvartal holdt sig stabil på 27%. Den rapporterede omsætning målt i danske kroner steg 5%, påvirket af frasalget af hudplejeforretningen.  Den organiske vækst pr. forretningsområde var 4% i Stomi, 8% i Kontinens, 7% i Stemme og Respiratorisk Pleje, 10% i Avanceret Sårpleje og -1% i Urol...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch